These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32248662)

  • 41. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
    Tang Z
    J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A model-based conditional power assessment for decision making in randomized controlled trial studies.
    Zou B; Cai J; Koch GG; Zhou H; Zou F
    Stat Med; 2017 Dec; 36(30):4765-4776. PubMed ID: 28868630
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conditional power and predictive power based on right censored data with supplementary auxiliary information.
    Sun L; Wan Y
    Stat Med; 2018 Aug; 37(18):2690-2699. PubMed ID: 29682770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints.
    Wei W; Esserman D; Kane M; Zelterman D
    Stat Methods Med Res; 2021 Jul; 30(7):1575-1588. PubMed ID: 34159859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using surrogate information to improve confirmatory platform trial with sample size re-estimation.
    Zhong C; Li Q; Wu L; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):547-566. PubMed ID: 35714331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sample size determination in clinical trials with multiple co-primary binary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    Stat Med; 2010 Sep; 29(21):2169-79. PubMed ID: 20687162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Information-based sample size re-estimation in group sequential design for longitudinal trials.
    Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
    Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interim monitoring of clinical trials based on long-term binary endpoints.
    Marschner IC; Becker SL
    Stat Med; 2001 Jan; 20(2):177-92. PubMed ID: 11169596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation.
    Yu J; Lai D
    Contemp Clin Trials; 2019 Dec; 87():105874. PubMed ID: 31678412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.
    Hade EM; Young GS; Love RR
    Trials; 2019 Aug; 20(1):527. PubMed ID: 31443726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.